Calox has acquired the Peruvian laboratory Vitapharma, aiming to strengthen its expansion and market presence in the Andean region.

Information on the Target

Calox has acquired Vitapharma, a Peruvian laboratory situated in Lurín, boasting a manufacturing facility that spans 5,500 square meters. In 2023, Vitapharma reported revenues of $24 million, and following its merger with Keyfarm, it is projected to reach $30 million in sales by 2025. The company plans to invest $2 million to expand its operations and upgrade its equipment.

This acquisition is a strategic move for Calox, which is currently operating across eight countries. By incorporating Vitapharma into its portfolio, Calox aims to strengthen its presence and enhance its market share in the Latin American region.

Industry Overview in Peru

The pharmaceutical industry in Peru has shown considerable growth in recent years, driven by increasing healthcare demands and expanding access t